GT Biopharma Announces Two Poster Presentations at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting
October 06, 2022 08:18 ET
|
GT Biopharma, Inc.
BRISBANE, Calif., Oct. 06, 2022 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company” or “GTB”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics...
GT Biopharma Announces Adjournment of Special Shareholders Meeting
October 04, 2022 16:10 ET
|
GT Biopharma, Inc.
- Meeting adjourned to October 10, 2022 at 11 a.m. PST- GTB encourages all stockholders of record on August 8, 2022 who have not yet voted- to do so by 11:59 p.m. PST Time on October 9, 2022 ...
GT Biopharma Poster Presentation and Mini Oral Session at ESMO Congress 2022 Demonstrates GTB-5550 TriKE® Ability to Specifically Target and Efficiently Kill Multiple B7H3+ Solid and Hematologic Malignancies
September 12, 2022 09:34 ET
|
GT Biopharma, Inc.
GTB-5550 generates a robust and NK cell specific proliferation signal compared to IL-15 aloneGTB-5550 specifically targets B7-H3+ cellsGTB-5550 effectively induced NK cell degranulation and interferon...
GT Biopharma to Participate in the H.C. Wainwright 24th Annual Global Investment Conference in September
September 08, 2022 07:30 ET
|
GT Biopharma, Inc.
BRISBANE, Calif., Sept. 08, 2022 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's...
GT Biopharma Affirms Manufacturing Timeline For Lead Investigational Asset GTB-3650
August 30, 2022 18:00 ET
|
GT Biopharma, Inc.
GTB-3650’s IND application with the FDA expected by end of first quarter of 2023 BRISBANE, Calif., Aug. 30, 2022 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company” or “GTB”) (NASDAQ: GTBP), a...
GT Biopharma Reports Second Quarter Fiscal 2022 Financial Results and Business Update
August 11, 2022 09:35 ET
|
GT Biopharma, Inc.
Presented preclinical data demonstration second-generation CD19 targeting Tri-specific Killer Engager (TRIKE®) driving robust NK cell function against B cell malignancies at EHA 2022 Congress.GTB-5550...
GT Biopharma Presents Preclinical Data Demonstrating Second-Generation CD19 Targeting Tri-Specific Killer Engager (TriKE®) Driving Robust NK Cell Function Against B Cell Malignancies at EHA 2022 Congress
June 10, 2022 08:00 ET
|
GT Biopharma, Inc.
Ongoing experiments will evaluate the functionality and efficacy of GTB-7550 in vivoFuture studies will also involve assessments of GTB-7550 TriKE efficacy in other hematologic cancers BRISBANE,...
GT Biopharma Reports First Quarter Fiscal 2022 Financial Results and Business Update
May 16, 2022 08:01 ET
|
GT Biopharma, Inc.
Presented pre-clinical data at American Association for Cancer Research (AACR 2022), demonstrating GTB-5550 (cam16-IL15-camB7H3) Tri-specific Killer Engager (TriKE®) driving NK cell activation and...
GT Biopharma to Participate at H.C. Wainwright Hybrid Global Investment Conference
May 12, 2022 08:00 ET
|
GT Biopharma, Inc.
BRISBANE, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ: GTBP), an immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary...
GT Biopharma Presents Preclinical Data Demonstrating Novel B7H3+ Tumor Targeting GTB-5550 TriKE® Driving NK Cell Activation and ADCC Against Head and Neck Squamous Cell Carcinomas at AACR Annual Meeting 2022
April 11, 2022 07:30 ET
|
GT Biopharma, Inc.
- Ongoing experiments will evaluate the functionality and efficacy of the B7H3 TriKE in vivo- Future studies will also involve assessments of the B7H3 TriKE efficacy in the HNSCC tumor...